SCHEMBL25157453

SCHEMBL25157453

c1cnc2ccc(-c3c[nH]c4nc(NC5CCOCC5)ncc34)cc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 6/20 0.55
▸ RET P07949 3/20 0.53
▸ CLK2 P49760 3/20 0.53
▸ CLK3 P49761 2/20 0.53
▸ CDC7 O00311 4/20 0.50
▸ CDK2 P24941 2/20 0.50
▸ CDK7 P50613 2/20 0.50
▸ CDK9 P50750 2/20 0.50
▸ JAK2 O60674 2/20 0.50
▸ MAP4K4 O95819 2/20 0.50
▸ PIM1 P11309 2/20 0.50
▸ PRKACA P17612 2/20 0.50
▸ FLT3 P36888 2/20 0.50
▸ GSK3B P49841 2/20 0.50
▸ JAK3 P52333 2/20 0.50
▸ HIPK2 Q9H2X6 2/20 0.50
▸ DAPK3 O43293 1/20 0.50
▸ ROCK2 O75116 1/20 0.50
▸ PRKD3 O94806 1/20 0.50
▸ PAK4 O96013 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30349016 1.00 DYRK1A (0.55) DYRK1ARETCLK2CLK3CDC7
SCHEMBL25157324 0.90 DYRK1A (0.54) DYRK1ARETCLK2CLK3CDC7
SCHEMBL25157004 0.89 DYRK1A (0.51) DYRK1ARETCLK2CLK3CDC7
SCHEMBL30348752 0.89 DYRK1A (0.51) DYRK1ARETCLK2CLK3CDC7
SCHEMBL25158041 0.88 DYRK1A (0.55) DYRK1ARETCLK2CLK3CDC7
SCHEMBL25157421 0.88 DYRK1A (0.53) DYRK1ARETCLK2CLK3CDC7
SCHEMBL25157796 0.87 DYRK1A (0.51) DYRK1ARETCLK2CLK3CDC7
SCHEMBL30346470 0.87 DYRK1A (0.51) DYRK1ARETCLK2CLK3CDC7
SCHEMBL25158769 0.87 DYRK1A (0.65) DYRK1ARETCLK2CLK3CDC7
SCHEMBL30349367 0.87 DYRK1A (0.65) DYRK1ARETCLK2CLK3CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885RET 1034/4885CLK2 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback